Abstract:Abstract Lung cancer ranks among the most common cancers world-wide and is the first cancer-related cause of death. The classification of lung cancer has evolved tremendously over the past two decades. Today, non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, comprises a multitude of molecular oncogenic subsets that change both the prognosis and management of disease. Since the first targeted oncogenic alteration identified in 2004, with the epidermal growth factor receptor (EGFR), there has been unprecedented progress in identifying and targeting new molecular alterations. Almost two decades of experience have allowed scientists to elucidate the biological function of oncogenic drivers and understand and often overcome the molecular basis of acquired resistance mechanisms. Today, targetable molecular alterations are identified in approximately 60% of lung adenocarcinoma patients in Western populations and 80% among Asian populations. Oncogenic drivers are largely enriched among non-smokers, east Asians, and younger patients, though each alteration has its own patient phenotype. The current landscape of druggable molecular targets includes EGFR, anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B (BRAF), ROS proto-oncogene 1 (ROS1), Kirstin rat sarcoma virus (KRAS), human epidermal receptor 2 (HER2), c-MET proto-oncogene (MET), neurotrophic receptor tyrosine kinase (NTRK), rearranged during transfection (RET), neuregulin 1 (NRG1). In addition to these known targets, others including Phosphoinositide 3-kinases (PI3K) and fibroblast growth factor receptor (FGFR) have garnered significant attention and are the subject of numerous ongoing trials. In this era of personalized, precision medicine, it is of paramount importance to identify known or potential oncogenic drivers in each patient. The development of targeted therapy is mirrored by diagnostic progress. Next generation sequencing offers high-throughput, speed and breadth to identify molecular alterations in entire genomes or targeted regions of DNA or RNA. It is the basis for the identification of the majority of current druggable alterations and offers a unique window into novel alterations, and de novo and acquired resistance mechanisms. In this review, we discuss the diagnostic approach in advanced NSCLC, focusing on current oncogenic driver alterations, through their pathophysiology, management, and future perspectives. We also explore the shortcomings and hurdles encountered in this rapidly evolving field.

Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies

Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot

Novel Active Agents in Patients with Advanced NSCLC Without Driver Mutations Who Have Progressed after First-Line Chemotherapy

Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence

Isolated Progression of Metastatic Lung Cancer: Clinical Outcomes Associated with Definitive Radiotherapy.

Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review

Bombarding Oligoprogression

Treatment Strategies Based on Different Oligoprogressive Patterns after Immunotherapy Failure in Metastatic NSCLC.

Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments

Radiotherapy in the management of lung oligometastases

Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Oncogenic alterations in advanced NSCLC: a molecular super-highway

Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy.

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer